Pretargeted imaging beyond the blood–brain barrier
Vladimir Shalgunov, Sara Lopes van den Broek, Ida Vang Andersen, Rocío García‐Vázquez, Nakul Ravi Raval, Mikael Palner, Yuki Mori, Gabriela Schäfer, Barbara Herrmann, Hannes Mikula, Natalie Beschörner, Maiken Nedergaard, Stina Syvänen, Matthias Barz, Gitte M. Knudsen, Umberto Maria Battisti, Matthias M. Herth
Abstract
F]18 is our lead compound for future pretargeted neuroimaging studies based on BBB-penetrant monoclonal antibodies. Pretargeting beyond the BBB will allow us to image targets in the brain that are currently not imageable, such as soluble oligomers of neurodegeneration biomarker proteins. Imaging of such currently non-imageable targets will allow early diagnosis and personalized treatment monitoring. This in turn will accelerate drug development and greatly benefit patient care.